Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial
Stephanie M. de Boer*, Melanie E. Powell, Linda Mileshkin, Dionyssios Katsaros, Paul Bessette, Christine Haie-Meder, Petronella B. Ottevanger, Jonathan A. Ledermann, Pearly Khaw, Alessandro Colombo, Anthony Fyles, Marie-Helene Baron, Ina M. Jurgenliemk-Schulz, Henry C. Kitchener, Hans W. Nijman, Godfrey Wilson, Susan Brooks, Silvestro Carinelli, Diane Provencher, Chantal HanzenLudy C. H. W. Lutgens, Vincent T. H. B. M. Smit, Naveena Singh, Viet Do, Romerai D'Amico, Remi A. Nout, Amanda Feeney, Karen W. Verhoeven-Adema, Hein Putter, Carien L. Creutzberg, PORTEC Study Grp
Research output: Contribution to journal › Article › Academic › peer-review
Fingerprint
Dive into the research topics of 'Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial'. Together they form a unique fingerprint.